Skip to main content
SA

Steven A. Kaplan

Trainees (1)
Bilal Chughtai · 2012

Biography​

Steven A. Kaplan directs the Men's Wellness Program at Mount Sinai Health System and is a professor of urology at Icahn School of Medicine at Mount Sinai.1 He graduated from Mount Sinai School of Medicine in 1982 and completed a surgery internship and residency at Mount Sinai Hospital.1 He completed a urology residency and fellowship at Columbia University, where he worked under Jerry G. Blaivas as an AFUD fellow.23

Contributions​

His cited work examines treatments for benign prostatic hyperplasia and lower urinary tract symptoms, including transurethral electrovaporization, drug-coated balloon therapy, and Aquablation.45678

Cited on WARWIKI

14 publications with Steven A. Kaplan as a listed author are cited on WARWIKI, ordered by the number of pages that cite them. Papers whose author list is shortened to "et al." before this name are not included.

  1. Kaplan SA, Moss J, Freedman S, et al. "The PINNACLE study: a double-blind, randomized, sham-controlled study evaluating the Optilume BPH catheter system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia." J Urol. 2023;210(3):500–9. doi
    Cited on: Optilume BPH — Prostatic Drug-Coated Balloon System · Optilume BPH — Paclitaxel-Coated Balloon for LUTS Secondary to BPH · Drug-Coated Balloon Therapy
  2. Kaplan SA, Moss JL, Freedman SJ. Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study). Prostate Cancer Prostatic Dis. 2024;27(3):531-536. doi
    Cited on: Optilume BPH — Prostatic Drug-Coated Balloon System · Optilume BPH — Paclitaxel-Coated Balloon for LUTS Secondary to BPH
  3. Te AE, Te AG, Ramaswamy A, Kaplan SA. "Practical management of hematuria after endoscopic surgery for benign prostatic obstruction." Prostate Cancer Prostatic Dis. 2026. doi
    Cited on: Desmopressin
  4. Omidele OO, Kaplan SA. Retropubic Prostatectomy. In: Smith JA Jr, Dmochowski RR, Thomas JC, Preminger GM, eds. Hinman's Atlas of Urologic Surgery. 5th ed. Elsevier; 2025:489–498.
    Cited on: Simple Prostatectomy (Open / Laparoscopic / Robotic)
  5. Te AE, Kaplan SA. Balloons in benign prostatic hyperplasia: will they float? A comprehensive review of prostatic balloon prostatoplasty. Urol Clin North Am. 2025;52(4):559-566. doi
    Cited on: Optilume BPH — Paclitaxel-Coated Balloon for LUTS Secondary to BPH
  6. Kaplan SA, Pichardo M, Rijo E, et al. Long-term outcomes after treatment with Optilume BPH: four-year results from the EVEREST study. Can Urol Assoc J. 2024;18(11):E319-E325. doi
    Cited on: Optilume BPH — Paclitaxel-Coated Balloon for LUTS Secondary to BPH
  7. Omidele OO, Siegal AS, Roshandel R, Te AE, Kaplan SA. Aquablation at 4-years: real world data from the largest single-center study with associated outcomes follow-up. Urology. 2024;194:216-220. doi
    Cited on: Aquablation — AquaBeam Robotic Waterjet for BPH
  8. Kaplan SA, Pichardo M, Rijo E, et al. One-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2021;24(4):1073-1079. doi
    Cited on: Optilume BPH — Paclitaxel-Coated Balloon for LUTS Secondary to BPH
  9. Lee R, Te AE, Kaplan SA, Sandhu JS. Temporal trends in adoption of and indications for the artificial urinary sphincter. J Urol. 2009;181(6):2622–7. PMID 19375102.
    Cited on: Artificial Urinary Sphincter (Procedure)
  10. Weiner DM, Kaplan SA. "Electrosurgery: VaporTrode." Eur Urol. 1999;35(2):166–72. doi
    Cited on: Vaporization Electrode
  11. Kaplan SA, Laor E, Fatal M, Te AE. "Transurethral resection of the prostate versus transurethral electrovaporization of the prostate: a blinded, prospective comparative study with 1-year followup." J Urol. 1998;159(2):454–8. doi
    Cited on: Vaporization Electrode
  12. Te AE, Kaplan SA. "Transurethral electrovaporization of the prostate." Mayo Clin Proc. 1998;73(7):691–5. doi
    Cited on: Vaporization Electrode

Footnotes​

  1. Steven A Kaplan. New York. Accessed October 2026. ↩ ↩2

  2. THE UROLOGY RESIDENCY PROGRAM. Accessed October 2026. ↩

  3. Best Urologist NYC. Jerry G. Blaivas MD, world-renowned urological surgeon for incontinence, urinary fistulas. Accessed October 2026. ↩

  4. Kaplan SA, Moss J, Freedman S, et al. "The PINNACLE study: a double-blind, randomized, sham-controlled study evaluating the Optilume BPH catheter system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia." J Urol. 2023;210(3):500–9. doi:10.1097/ju.0000000000003568 ↩

  5. Kaplan SA, Moss JL, Freedman SJ. Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study). Prostate Cancer Prostatic Dis. 2024;27(3):531-536. doi:10.1038/s41391-024-00833-z ↩

  6. Te AE, Kaplan SA. "Transurethral electrovaporization of the prostate." Mayo Clin Proc. 1998;73(7):691–5. doi:10.1016/s0025-6196(11)64896-964896-9)) ↩

  7. Weiner DM, Kaplan SA. "Electrosurgery: VaporTrode." Eur Urol. 1999;35(2):166–72. doi:10.1159/000019838 ↩

  8. Kaplan SA, Laor E, Fatal M, Te AE. "Transurethral resection of the prostate versus transurethral electrovaporization of the prostate: a blinded, prospective comparative study with 1-year followup." J Urol. 1998;159(2):454–8. doi:10.1016/s0022-5347(01)63947-863947-8)) ↩